TSS
MGX icon

Two Sigma Securities’s Metagenomi Therapeutics MGX Stock Holding History

Two Sigma Securities’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
+15,173
New +$20.3K ﹤0.01% 1499
2026
Q1 		– Sell
-11,700
Closed -$19K – 2291
2025
Q4 		$19K Sell
11,700
-489
-4% -$1.06K ﹤0.01% 1190
2025
Q3 		$28.9K Buy
+12,189
New +$24.7K ﹤0.01% 1072

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Securities's MGX Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Metagenomi Therapeutics (MGX) in Q2 2026: 15,173 shares worth $18.1K. The stake represents ﹤0.01% of the portfolio and ranks #1499 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in MGX as recently as Q4 2025.

Two Sigma Securities first reported a position in MGX in Q3 2025 and has held it in 3 quarters since. The position peaked at $28.9K in Q3 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Two Sigma Securities held 15,173 shares of Metagenomi Therapeutics worth $18.1K as of Q2 2026.
  • Metagenomi Therapeutics was a new Two Sigma Securities position in Q2 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1499 holding.
  • Two Sigma Securities first reported a position in Metagenomi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Two Sigma Securities's Metagenomi Therapeutics position peaked at $28.9K in Q3 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.